Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brown, L. C. Articles by McAlister, F. A. Search for Related Content PubMed PubMed Citation Articles by Brown, L. C. Articles by McAlister, F. A. Related Collections Diabetes

Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis

From the Department of Public Health Sciences (Brown, Johnson) and the Department of Medicine (Majumdar, Tsuyuki, McAlister), University of Alberta, and the Institute of Health Economics (Johnson, Majumdar, Tsuyuki, McAlister), Edmonton, Alta.

Background: Given that most deaths among patients with diabetes mellitus are due to cardiovascular disease, we sought to determine the extent to which medications proven to reduce cardiovascular mortality are prescribed for patients with type 2 diabetes who have symptomatic atherosclerosis (i.e., coronary artery disease [CAD], cerebrovascular disease [CBVD] or peripheral arterial disease [PAD]).

Methods: Administrative records from Saskatchewan Health were used to evaluate the use of antiplatelet agents, statins and angiotensin-converting enzyme (ACE) inhibitors by people with treated type 2 diabetes with and without symptomatic atherosclerosis. CAD and CBVD were defined by International Classification of Diseases (ninth revision) codes, and PAD was defined on the basis of pentoxifylline use or lower limb amputation. Multivariate logistic regression analysis was used to compare medication use in patients with and without PAD, with adjustments for differences in age, sex and comorbidity.

Results: In this cohort of 12 106 patients with type 2 diabetes (mean age 64 years, 55% male, mean follow-up 5 years), fewer than 25% received an antiplatelet agent or statin, and fewer than 50% received an ACE inhibitor. Although patients with CAD were more likely to receive antiplatelet agents, statins or ACE inhibitors than people without CAD (p < 0.001 for all), the overall use of these medications was suboptimal (37%, 29% and 60% respectively among patients with symptomatic CAD). Similar patterns of practice were found for patients with symptomatic CBVD and PAD. All 3 proven efficacious therapies were prescribed for only 11% of patients with CAD, 22% with CBVD and 12% with PAD. Patients with PAD who had undergone lower limb amputation were no more likely to subsequently receive antiplatelet agents or statins than those without an amputation.

Interpretation: Diabetic patients with symptomatic atherosclerotic disease are undertreated with medications known to reduce cardiovascular morbidity and mortality, perhaps because of a "glucocentric" view of diabetes. Programs to improve the quality of cardiovascular risk reduction in these high-risk patients are needed.

This article has been cited by other articles:

				A. Holbrook, L. Thabane, K. Keshavjee, L. Dolovich, B. Bernstein, D. Chan, S. Troyan, G. Foster, H. Gerstein, and for the COMPETE II Investigators Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial Can. Med. Assoc. J., July 7, 2009; 181(1-2): 37 - 44. [Abstract] [Full Text] [PDF]

				C. Marshall, P. H. Lin, T. T. Huynh, and P. Kougias How Optimal is the Medical Management of Patients Prior to Major Reconstructive Vascular Surgery? The Results of a Cross-sectional Study Vascular and Endovascular Surgery, June 1, 2009; 43(3): 238 - 243. [Abstract] [PDF]

				E. Fharm, O. Rolandsson, and E. E Johansson 'Aiming for the stars'--GPs' dilemmas in the prevention of cardiovascular disease in type 2 diabetes patients: focus group interviews Fam. Pract., April 1, 2009; 26(2): 109 - 114. [Abstract] [Full Text] [PDF]

				H. Zaman Huri, Lee Qiu Yi, R. Pendek, and Che Zuraini Sulaiman Use of Antiplatelet Agents for Primary and Secondary Prevention of Cardiovascular Disease Amongst Type 2 Diabetic Patients Journal of Pharmacy Practice, August 1, 2008; 21(4): 287 - 301. [Abstract] [PDF]

				K. I. Paraskevas Applications of statins in cardiothoracic surgery: more than just lipid-lowering Eur. J. Cardiothorac. Surg., March 1, 2008; 33(3): 377 - 390. [Abstract] [Full Text] [PDF]

				P. Gaede, H. Lund-Andersen, H.-H. Parving, and O. Pedersen Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes N. Engl. J. Med., February 7, 2008; 358(6): 580 - 591. [Abstract] [Full Text] [PDF]

				E. Erdmann Review: Statin plus thiazolidinedione use in patients with diabetes at high cardiovascular risk The British Journal of Diabetes & Vascular Disease, September 1, 2007; 7(5): 211 - 216. [Abstract] [PDF]

				C. Sirois, J. Moisan, P. Poirier, and J.-P. Gregoire Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1880 - 1882. [Full Text] [PDF]

				T. Jeerakathil, J. A. Johnson, S. H. Simpson, and S. R. Majumdar Short-Term Risk for Stroke Is Doubled in Persons With Newly Treated Type 2 Diabetes Compared With Persons Without Diabetes: A Population-Based Cohort Study Stroke, June 1, 2007; 38(6): 1739 - 1743. [Abstract] [Full Text] [PDF]

				F A McAlister, S R Majumdar, D T Eurich, and J A Johnson The effect of specialist care within the first year on subsequent outcomes in 24 232 adults with new-onset diabetes mellitus: population-based cohort study Qual. Saf. Health Care, February 1, 2007; 16(1): 6 - 11. [Abstract] [Full Text] [PDF]

				B. R. Shah, J. E. Hux, and P. C. Austin Diabetes Is Not Treated as a Coronary Artery Disease Risk Equivalent Diabetes Care, February 1, 2007; 30(2): 381 - 383. [Full Text] [PDF]

				J. A. Johnson, S. L. Pohar, and S. R. Majumdar Health Care Use and Costs in the Decade After Identification of Type 1 and Type 2 Diabetes: A population-based study. Diabetes Care, November 1, 2006; 29(11): 2403 - 2408. [Abstract] [Full Text] [PDF]

				L. C. Brown, S. R. Majumdar, S. C. Newman, and J. A. Johnson Type 2 diabetes does not increase risk of depression. Can. Med. Assoc. J., July 4, 2006; 175(1): 42 - 46. [Abstract] [Full Text] [PDF]

				J. Menard, H. Payette, J.-P. Baillargeon, P. Maheux, S. Lepage, D. Tessier, and J.-L. Ardilouze Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial Can. Med. Assoc. J., December 6, 2005; 173(12): 1457 - 1466. [Abstract] [Full Text] [PDF]

				M. Parmar Cardiovascular risk in patients with type 2 diabetes Can. Med. Assoc. J., April 26, 2005; 172(9): 1160 - 1160. [Full Text] [PDF]

				M. Shanks, D. T. Holmes, L. Cermakova, and J. Frohlich Cardiovascular risk in patients with type 2 diabetes Can. Med. Assoc. J., April 26, 2005; 172(9): 1160 - 1161. [Full Text] [PDF]

				D. Spurgeon Heart disease in diabetic patients is undertreated BMJ, November 13, 2004; 329(7475): 1124. [Full Text]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2004, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.